A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
This is a randomized, double-Blind, placebo-controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis.
Epistemonikos ID: c0a71a14036ebf8b4b77705cd08f95e735502b8d
First added on: Mar 31, 2022